跳至主要内容
临床试验/CTRI/2019/05/019005
CTRI/2019/05/019005尚未招募3 期

A RANDOMIZED PROSPECTIVE OPEN LABEL STUDY COMPARING SINGLE AGENT GEMCITABINE VERSUS CAPECITABINE IN PATIENTS OF LOCALLY ADVANCED AND METASTATIC CARCINOMA GALL BLADDER WITH POOR PERFORMANCE STATUS

DR B BOROOAH CANCER INSTITUTE0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • ECOG performance score more than equals to 2.
  • Written informed consent
  • Staging done prior to randomization.
  • Creatinine levels indicating renal clearance more than or equals to 50 ml/min.
  • Bilirubin less than 3 times of upper normal limit.
  • Biopsy/FNAC proven Gall Bladder adenocarcinoma
  • Locally advanced unresectable tumours or Metastatic disease.

排除标准

  • Recurrent gall bladder cancer.
  • Inability to give informed consent.
  • Previous history of hepatobiliary cancers
  • Medical comorbidities precluding use of chemotherapy.
  • Concomitant malignancies.

研究者

发起方
DR B BOROOAH CANCER INSTITUTE

相似试验